ATE525090T1 - Zusammensetzungen, verfahren und sets zur linderung von gastrointestinalen nebenwirkungen von lipase-hemmern - Google Patents
Zusammensetzungen, verfahren und sets zur linderung von gastrointestinalen nebenwirkungen von lipase-hemmernInfo
- Publication number
- ATE525090T1 ATE525090T1 AT03814781T AT03814781T ATE525090T1 AT E525090 T1 ATE525090 T1 AT E525090T1 AT 03814781 T AT03814781 T AT 03814781T AT 03814781 T AT03814781 T AT 03814781T AT E525090 T1 ATE525090 T1 AT E525090T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- animal
- stiffening
- compositions
- safe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43415602P | 2002-12-17 | 2002-12-17 | |
| PCT/US2003/039798 WO2004060401A1 (en) | 2002-12-17 | 2003-12-15 | Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525090T1 true ATE525090T1 (de) | 2011-10-15 |
Family
ID=32713015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03814781T ATE525090T1 (de) | 2002-12-17 | 2003-12-15 | Zusammensetzungen, verfahren und sets zur linderung von gastrointestinalen nebenwirkungen von lipase-hemmern |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8372430B2 (de) |
| EP (1) | EP1572240B1 (de) |
| JP (1) | JP2006514053A (de) |
| CN (1) | CN1726049A (de) |
| AT (1) | ATE525090T1 (de) |
| AU (1) | AU2003297078B2 (de) |
| CA (2) | CA2507971A1 (de) |
| ES (1) | ES2373877T3 (de) |
| MX (1) | MXPA05006480A (de) |
| WO (1) | WO2004060401A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7208225B2 (en) * | 1995-06-30 | 2007-04-24 | Lafarge Platres | Prefabricated plaster board |
| ES2434072T3 (es) * | 2005-06-09 | 2013-12-13 | Norgine Bv | Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona |
| KR101252635B1 (ko) * | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| US8741966B2 (en) | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| EP2147910A1 (de) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Neue Lipid-Verbindungen |
| TWI558395B (zh) | 2009-05-08 | 2016-11-21 | 普諾華生物製藥諾治股份有限公司 | 新穎的脂質化合物 |
| EA028535B1 (ru) | 2010-11-05 | 2017-11-30 | Пронова Биофарма Норге Ас | Способы лечения с применением липидных соединений |
| WO2012082083A1 (en) * | 2010-12-15 | 2012-06-21 | Les Laboratoires Medis Sa | Pharmaceutical formulation containing tetrahydrolipstatin as an active ingredient |
| EP3578170A1 (de) | 2013-02-28 | 2019-12-11 | Basf As | Zusammensetzung mit einer lipidverbindung, einem triglycerid und einem tensid sowie verfahren zur verwendung davon |
| EP3679924A3 (de) | 2014-08-11 | 2020-07-29 | perora GmbH | Formulierung mit partikeln |
| JP2017524014A (ja) | 2014-08-11 | 2017-08-24 | ペロラ ゲーエムベーハーＰｅｒｏｒａ Ｇｍｂｈ | 満腹感を誘発する方法 |
| KR102644400B1 (ko) | 2015-04-28 | 2024-03-06 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
| US20180214382A1 (en) | 2015-07-07 | 2018-08-02 | Perora Gmbh | Edible composition comprising a polysaccharide and a lipid |
| EP3319592A1 (de) | 2015-07-07 | 2018-05-16 | perora GmbH | Verfahren zum hervorrufen von sättigung |
| CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| GB201808571D0 (en) * | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| EP4232091A1 (de) * | 2020-10-26 | 2023-08-30 | Monash University | Auf lymphe abzielende formulierungen |
| WO2023038575A2 (en) * | 2021-09-09 | 2023-03-16 | Junion Labs Pte. Ltd. | Superabsorbent hydrogels with lipase inhibitor |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211765A (en) | 1971-10-12 | 1980-07-08 | Monsanto Company | Method for controlling obesity |
| DE2217692C3 (de) * | 1972-04-13 | 1984-10-18 | Henkel KGaA, 4000 Düsseldorf | Komplexbildner mit mehrwertigen Metallionen |
| FI54811C (fi) | 1972-06-03 | 1979-03-12 | Vega Jose Manuel Regife | Foerfarande foer tillvaratagning och rening av zink fraon zinkhaltiga loesningar |
| US3980968A (en) | 1975-01-02 | 1976-09-14 | Zenith Radio Corporation | Non-proportionate AFC system |
| US4005196A (en) | 1976-02-12 | 1977-01-25 | The Procter & Gamble Company | Vitaminized compositions for treating hypercholesterolemia |
| US4223023A (en) | 1978-10-12 | 1980-09-16 | Ivan Furda | Nonabsorbable lipid binder |
| US4241054A (en) | 1978-12-08 | 1980-12-23 | The Procter & Gamble Company | Detoxifying lipophilic toxins |
| FR2485548A1 (fr) | 1980-06-30 | 1981-12-31 | Lhd Lab Hygiene Dietetique | Procede de preparation d'un polymere de structure tridimensionnelle du type polyurethane reticule, produit obtenu selon ce procede et son application en tant qu'agent gonflant, notamment en therapeutique |
| US4432968A (en) | 1980-10-20 | 1984-02-21 | The Dow Chemical Company | Weight control with fat imbibing polymers |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| US5149720A (en) | 1991-08-12 | 1992-09-22 | The Procter & Gamble Company | Process for preparing emulsions that are polymerizable to absorbent foam materials |
| US5387207A (en) | 1991-08-12 | 1995-02-07 | The Procter & Gamble Company | Thin-unit-wet absorbent foam materials for aqueous body fluids and process for making same |
| US5268224A (en) | 1991-08-12 | 1993-12-07 | The Procter & Gamble Company | Absorbent foam materials for aqueous body fluids and absorbent articles containing such materials |
| US5260345A (en) | 1991-08-12 | 1993-11-09 | The Procter & Gamble Company | Absorbent foam materials for aqueous body fluids and absorbent articles containing such materials |
| JP2667351B2 (ja) | 1992-03-24 | 1997-10-27 | 麒麟麦酒株式会社 | 食餌脂質消化吸収阻害剤および飲食品 |
| US5189070A (en) | 1992-05-29 | 1993-02-23 | Shell Oil Company | Process for preparing low density porous crosslinked polymeric materials |
| CA2098167C (en) | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| US5741518A (en) | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| US5290820A (en) | 1993-07-29 | 1994-03-01 | Shell Oil Company | Process for preparing low density porous crosslinked polymeric materials |
| US5650222A (en) | 1995-01-10 | 1997-07-22 | The Procter & Gamble Company | Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios |
| IL116709A (en) | 1995-01-10 | 2000-02-29 | Procter & Gamble | Continuous process for the preparation of high internal phase emulsion |
| US5563179A (en) | 1995-01-10 | 1996-10-08 | The Proctor & Gamble Company | Absorbent foams made from high internal phase emulsions useful for acquiring and distributing aqueous fluids |
| US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
| US5817704A (en) | 1996-03-08 | 1998-10-06 | The Procter & Gamble Company | Heterogeneous foam materials |
| WO1998022072A1 (en) | 1996-11-19 | 1998-05-28 | The Procter & Gamble Company | Compliance package and method of improving or aiding patient compliance for complex drug regimens |
| WO1999034787A2 (en) | 1998-01-09 | 1999-07-15 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| TR200100472T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler |
| WO2000009122A1 (en) * | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| AR025609A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| AR025587A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| GB0001572D0 (en) | 2000-01-24 | 2000-03-15 | Alizyme Therapeutics Ltd | Inhibitors |
| US6207724B1 (en) | 2000-01-24 | 2001-03-27 | The Procter & Gamble Company | Foam materials and high internal phase emulsions made using oxidatively stable emulsifiers |
| US20030072804A1 (en) | 2001-03-19 | 2003-04-17 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
-
2003
- 2003-10-31 US US10/699,351 patent/US8372430B2/en not_active Expired - Fee Related
- 2003-12-15 AT AT03814781T patent/ATE525090T1/de not_active IP Right Cessation
- 2003-12-15 JP JP2004565470A patent/JP2006514053A/ja active Pending
- 2003-12-15 AU AU2003297078A patent/AU2003297078B2/en not_active Ceased
- 2003-12-15 WO PCT/US2003/039798 patent/WO2004060401A1/en active Application Filing
- 2003-12-15 EP EP03814781A patent/EP1572240B1/de not_active Expired - Lifetime
- 2003-12-15 MX MXPA05006480A patent/MXPA05006480A/es unknown
- 2003-12-15 CA CA002507971A patent/CA2507971A1/en not_active Abandoned
- 2003-12-15 CA CA2708895A patent/CA2708895A1/en not_active Abandoned
- 2003-12-15 CN CNA2003801059252A patent/CN1726049A/zh active Pending
- 2003-12-15 ES ES03814781T patent/ES2373877T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003297078A1 (en) | 2004-07-29 |
| ES2373877T3 (es) | 2012-02-09 |
| EP1572240A1 (de) | 2005-09-14 |
| AU2003297078B2 (en) | 2008-06-05 |
| CA2708895A1 (en) | 2004-07-22 |
| JP2006514053A (ja) | 2006-04-27 |
| EP1572240B1 (de) | 2011-09-21 |
| CN1726049A (zh) | 2006-01-25 |
| MXPA05006480A (es) | 2005-08-26 |
| US20040126424A1 (en) | 2004-07-01 |
| WO2004060401A1 (en) | 2004-07-22 |
| CA2507971A1 (en) | 2004-07-22 |
| US8372430B2 (en) | 2013-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE525090T1 (de) | Zusammensetzungen, verfahren und sets zur linderung von gastrointestinalen nebenwirkungen von lipase-hemmern | |
| ATE322902T1 (de) | Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| TR200100824T2 (tr) | İleumda safra asidi taşınmasının ve taurokolat alımının inhibitörleri olarak aktifliğe sahip benzotiepinler | |
| DK1446136T3 (da) | Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen | |
| BR0206644A (pt) | Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares | |
| WO2003051313A3 (en) | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes | |
| MX339420B (es) | Compuestos para la modulacion de la actividad de ppar gamma. | |
| UA92348C2 (en) | 17b-HSD1 AND STS INHIBITORS | |
| BR0011342A (pt) | Métodos para a modulação de diabetes tipo 2, para modular a resistência à insulina, para alìvio de hiperlipidemia e para tratamento de hiperuricemia em um mamìfero, e, composição farmacêutica | |
| ATE555810T1 (de) | Mittel zur behandlung oder prävention von verdauungsgeschwüren | |
| DK0735868T3 (da) | Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul | |
| PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
| DE60116256D1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten | |
| BR0206639A (pt) | Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares | |
| DE69926400D1 (de) | Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes | |
| BR0212907A (pt) | Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis | |
| MXPA03006631A (es) | Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares. | |
| ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| BR9607057A (pt) | Composições farmacêuticas compreendendo inibidores monoamina oxidase b | |
| BR0110208A (pt) | Composições e terapias para distúrbios associados com hiperlipidemia | |
| ATE486612T1 (de) | Verfahren zur behandlung von diabetes typ 2 | |
| BR0309406A (pt) | Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento | |
| EA200601687A1 (ru) | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 | |
| ATE548350T1 (de) | N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |